Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case–control study
Open Access
- 9 July 2020
- journal article
- letter
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 80 (2), 1.2-2
- https://doi.org/10.1136/annrheumdis-2020-218243
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Acute complications and mortality in hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysisCritical Care, 2020
- Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, ChinaJAMA Internal Medicine, 2020
- Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort studyEuropean Journal of Internal Medicine, 2020
- Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, ItalyAutoimmunity Reviews, 2020
- Effective treatment of severe COVID-19 patients with tocilizumabProceedings of the National Academy of Sciences of the United States of America, 2020
- Severe acute respiratory syndrome Coronavirus ORF3a protein activates the NLRP3 inflammasome by promoting TRAF3‐dependent ubiquitination of ASCThe FASEB Journal, 2019